Search

We report the case of a 36-year-old woman with spontaneously conceived heterotopic pregnancy with abdominal pregnancy. She visited the hospital at 5 weeks and 4 days of gestation and transvaginal ultrasonography revealed a normal intrauterine pregnancy. Two days later, she was urgently transported to the hospital due to extreme abdominal pain. Emergent laparotomy was performed to investigate the cause of massive intraperitoneal bleeding, which was confirmed to have been due to an abdominal pregnancy that implanted on the vesicouterine pouch. The hematic mass, including chorionic villi, was successfully removed from the peritoneum. The subsequent course of the intrauterine pregnancy was uneventful and a healthy baby was born at term. To the best of our knowledge, this is an extremely rare case report of a spontaneously conceived heterotopic abdominal pregnancy, in which the intrauterine pregnancy showed a successful outcome despite the collapse of the abdominal pregnancy at a very early stage.

Colostrum is the first food for newborns and it contains various crucial immune factors. The concentrations of immune factors in breast milk may change depending on maternal characteristics such as body mass index, collection day, and age at first pregnancy. In this exploratory study, we investigated the association between TGF-β1, TGF-β2, and IgA in colostrum and rarely studied factors that affect breast milk components, including the use of labor-inducing medication, colostrum secretion, sex of newborns, breast or nipple problems, and nipple care. Breast milk samples were collected from 42 mothers and analyzed for TGF-β1, TGF-β2, and IgA. The results suggest that parity and mode of delivery may be correlated with the concentrations of immune factors in colostrum. However, we found no association between the immune factors in colostrum and the use of labor-inducing medications, colostrum secretion, sex of newborns, breast or nipple problems, and nipple care. These findings have some implications for further analysis of the effects of immune factors in breast milk on the prognosis of allergies in children.

PURPOSE: To clarify the associations of the maternal age, history of miscarriage, and embryonic/fetal size at miscarriage with the frequencies and profiles of cytogenetic abnormalities detected in spontaneous early miscarriages. METHODS: Miscarriages before 12 weeks of gestation, whose karyotypes were evaluated by G-banding between May 1, 2005, and May 31, 2017, were included in this study. The relationships between their karyotypes and clinical findings were assessed using trend or chi-square/Fisher’s exact tests and multivariate logistic analyses. RESULTS: Three hundred of 364 miscarriage specimens (82.4%) had abnormal karyotypes. An older maternal age was significantly associated with the frequency of abnormal karyotype (p(trend)

To elucidate clinical feature and anti-phospholipid antibody (aPL) profiles, including lupus anticoagulant (LA), anti-cardiolipin (CL) antibodies and anti-phosphatidylserine/prothrombin (PS/PT) antibodies, of pregnancy failure in patients with antiphospholipid antibody syndrome (APS) already treated with conventional therapy.Thirty-four women with a history of pregnancy who were diagnosed with APS between 2008 and 2016 were included in the study. We defined the successful pregnancy group as women who gave birth to a healthy baby over 1500 g after 34 weeks of pregnancy under conventional treatment (heparin and/or low-dose aspirin). The unsuccessful pregnancy group was defined as women whose pregnancy outcomes did not meet the aforementioned criteria despite the conventional therapy. The clinical features and aPL profiles were compared between the two groups.Fifteen women were classified into the unsuccessful pregnancy group; seven women were in the successful pregnancy group. Having history of both thrombosis and pregnancy morbidity and LA positivity were significantly more prevalent in the unsuccessful pregnancy group than in the successful pregnancy group (p .05, respectively). In contrast, single positivity of anti-CL antibody was negatively associated with APS-associated pregnancy morbidity under the conventional treatment (p .01). The proportion of anti-PS/PT IgG-positive patients was significantly higher in the unsuccessful pregnancy group (p = .02, OR 18.7, 95% CI 1.50, 232.29) with high concordance rate with LA (97% consistence).History of both thrombosis and pregnancy morbidity and the positivity of LA and/or anti-PS/PT-IgG, not but anti-CL-antibodies were correlated with APS-associated pregnancy morbidity refractory to conventional treatment. Clinical feature and aPL profiles might help us to make risk assessment for adverse pregnancy outcomes in patients with APS.

Aim : The aim of the study was to describe the frequency of anti-phosphatidylserine-prothorombin antibody(aPS/PTAb) in patients with recurrent abortion and preeclampsia, and to study the relationship between the presence of aPS/PTAb and clinical finding. Eighty six cases of recurrent abortion and 82 cases of preeclampsia were studied. A aPS/PTAb was measured by an enzyme linked immunosorbent assay(ELISA). Results : In patients with recurrent abortion, 3 out of 86 cases(3.4%) were positive in IgG antibody measurements and 5 out of 86(5.8%) were positive in IgM antibody measurements. In patients with preeclampsia, 2 out of 82 cases(2.5%) were positive in IgG antibody measurements and 13 out of 82(16%) were positive in IgM antibody measurements. The positive rates of aPS/PTAb in severe hypertension-positive cases is greater than in hypertension-negative cases(p=0.045). The positive rates of aPS/PTAb is higher tendency with in severe type than in mild type(p=0.117). The positive rates of aPS/PTAb is higher tendency with proteinuria and/or hypertension than without proteinuria(p=0.098) or hypertension(p=0.096). Conclusion : We found that aPS/PTAb appears in some cases of patients with recurrent abortion and preeclampsia. Our data suggest that aPS/PTAb might be a risk factor in patients with recurrent abortion, and may relate to clinical finding in preeclampsia.

Today, the first line of chemotherapy for ovarian cancer is Taxol-carboplatin (T-J), but there are some problems including severe bone marrow depression and severe neuropathy, so-called poor compliance cases. By changing the method of administering Taxol, the key drug in chemotherapy for ovarian cancer, it is possible to make compliance more better, continue therapies and look after patients' PS and QOL. We have considered weekly Taxol based chemotherapy for early stage recurrence cases and poor compliance cases; For example, weekly Taxol in combination with carboplatin (monthly) for poor compliance cases, severe bone marrow depression and the like, and Taxol by drip infusion for 24 hours in cases of peripheral nerve disorder (severe neuropathy). Especially, weekly Taxol combination with carboplatin (monthly), with takes advantage of the repeated administration of Taxol and one time administration of carboplatin, is a highly beneficial therapy for ovarian cancer. With this protocol we can reduce side effects and continue long-term administration on an outpatient basis.